Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Sponsor: Regeneron Pharmaceuticals
Full Title
Protocol R3767-ONC-2235: A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in
Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of
Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%
Study Treatment
Fianlimab (also known as REGN3767, anti-LAG-3) is a fully human, hinge-stabilized IgG4 monoclonal antibody that
binds with high affinity to LAG-3
Eligibility/Info
- First line unresectable metastatic squamous or non-squamous on-small cell lung cancer
- PD-L1 ≥50%
- EGFR/ALK/ROS1 negative
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
